We compared the incidence of ventilator associated pneumonia (VAP) among patients treated with comprehensive oral care to those treated with conventional methods of oral care.
Introduction
Ventilator associated pneumonia (VAP) is pneumonia that appears in an intubated patient 48 or more hours from the onset of ventilation or up to one week after ventilation is discontinued (American Thoracic Society and Infectious Diseases Society of America, 2005; Fields, 2008) . The signs and symptoms of VAP are similar to those of other pneumonias and include the following:
1. A change in body temperature to above 38 degrees C or below 36 degrees C 2. The appearance of new infiltrate on chest x-ray 3. A white blood cell count of less than 4,000 or greater than 12,000 4. The appearance of or change in phlegm (purulence) (American Thoracic Society and Infectious Diseases Society of America, 2005) .
Mouth-related risk factors for VAP include the formation of bacterial colonies in the mouth, the accumulation of pathogenic bacteria on the surface of the teeth, development of plaque, and aspiration of secretions from the oral cavity (Rello et al, 2002; Schleder, 2003) . Studies have shown that, within 24 hours of admission to an intensive care unit (ICU), patients can become colonised with pathogenic bacteria such as Pseudomonas, Acinetobacter, and methicillin-resistant Staphylococcus aureus (MRSA) (Sole et al, 2002; El-Solh et al, 2004; Garcia et al, 2004; Rello, 2005; Fields, 2008) .
Among mechanically ventilated patients, VAP is the most common nosocomial infection (Luyt et al, 2005) . The reported incidence of VAP varies because of overlap with other lower respiratory infections, surveillance strategy, case definition, and diagnostic procedures. In its High Impact Intervention guideline, the United Kingdom Department of Health mentions that VAP is the most frequently occurring infection in patients having been admitted to the ICU (Vincent et al, 2006; United Kingdom Department of Health, 2011) . This National Health Service (NHS) guideline also says that, in addition to an increased mortality rate associated with VAP (Melson et al, 2009; United Kingdom Department of Health, 2011) , this nosocomial pneumonia is associated with increased duration of ventilation, ICU and total hospital length of stay, and healthcare expenses (Safdar et al, 2005; United Kingdom Department of Health, 2011) . Preventing this type of infection, therefore, is feasible using cost-effective bundles.
Efforts to describe the global burden of VAP reflect the challenge of gathering reliable data. It is accepted that VAP is associated with prolonged periods of mechanical ventilation, extended hospitalisations, and excessive use of antimicrobial medications (Fischer et al, 2000; Coffin et al, 2008; Edwards et al, 2009; Bekaert et al, 2011; O'Grady et al, 2012) . In terms of financial implications, VAP has been shown to cost an additional US$29,000 to $40,000 per patient (Rello et al, 2002; Schleder, 2003; Fields, 2008; Restrepo et al, 2010) . Moreover, VAP is associated with higher mortality. Although some controversy surrounds the determination of mortality rates attributable to VAP (Edwards et al, 2009; Bekaert et al, 2011; O'Grady et al, 2012) , the VAP mortality rate has been reported to be as high as 40% to 80% (Fagon et al, 1993; Porzecanski and Bowton, 2006; Fields, 2008) .
The results of recent quality improvement studies show that proper oral care lowers the rate of VAP in acute care facilities (Coffin et al, 2008) . Using an oral care protocol reduced the VAP rate from 12 to 8 per 1,000 ventilator days (p = 0.06) and also significantly reduced duration of ventilation, length of stay, and mortality (Garcia et al, 2009) .
As oral care continues to emerge as an issue that can change the prognosis of critically ill patients, conventional methods of oral hygiene are frequently evaluated for their efficacy in reducing VAP. Evidence has shown that preventing bacterial colonisation of the oropharynx prevents the development of VAP. Several studies have proven that the removal of dental plaque is a key to removing bacteria from the oropharynx, and the most effective way to remove the plaque is through tooth brushing and suctioning simultaneously. Others have found that tooth brushing removes plaque more effectively than the use of soft swabs or gauze (Pearson and Hutton, 2002; Schleder, 2003; Binkley et al, 2004; El-Sohl et al, 2004; Shinn, 2004; Fields, 2008; Heo et al, 2008) .
We conducted a study to examine the effects of an oral hygiene treatment that includes tooth brushing, cleaning of the oral cavity, and rinsing with antiseptic. We wished to compare the incidence of VAP among patients treated with oral care combined with the brushing of teeth to those treated with conventional methods of oral care. We hypothesized that a correlation would be found between the type of oral hygiene treatment administered and the VAP incidence in ventilated patients in the ICU.
Methods
We conducted a prospective, controlled study in the hospital ICU. The ICU is a general intensive care unit that admits patients from all hospital departments, including trauma, surgery, severe infection and internal medicine patients.
Our study population included all ventilated patients in the ICU between August 2007 and October 2009. Upon admission to the ICU, patients were alternately allocated to either the study group (n=45) or the control group (n=45). We excluded from our study patients who were younger than 18 years, patients with a clinical diagnosis of pneumonia at the time of intubation, immunosuppressed patients, pregnant women, and burn patients.
All patients admitted to the general intensive care unit (GICU) were allocated to either the study or control group, aside from those filling the exclusion criteria stated above. Each patient was allocated only on the basis of the time entering the GICU. Patient surveillance was performed by an independent person (infectious disease nurse) who was unaware of the patient allocation group. National Healthcare Safety Network (NHSN) criteria were used to diagnose VAP.
The study was approved by the hospital local ethics committee and written informed consent was signed by each patient or his/her legal guardian.
Data collection
Data collection included the following factors: 
Oral care
The oral care protocol of the study group was implemented three times per day with the use of the Q-Care Suction Oral System from Sage Products LLC (Toothette ® Oral Care Suction Toothbrush with Alcohol-Free Mouthwash and Mouth Moisturizer) (Sage Products LLC; Cary, IL). Each patient assigned to this group underwent a daily assessment of the oral cavity (lips, tongue, oral mucosa, gums, and teeth) and sputum. A member of the treatment team completed a structured form, which included details such as body temperature, chest x-ray findings, leucocyte count, Acute Physiology and Chronic Health Evaluation (APACHE) II score, ventilation mode, and culture results. The teeth were then brushed and oral discharge removed with a soft-bristle suction toothbrush, and suction swab. Sodium bicarbonate was used on the suction toothbrush to mechanically clean, refresh, and deodorize the oral cavity. In many ICUs in Europe, regular toothbrushes are often used in conjunction with suctioning through a soft or hard catheter. We find, however, that a small-headed toothbrush that incorporates suctioning offers greater comfort, ease of control, and efficacy. The oral cavity was cleaned with Sage Perox-A-Mint (1.5% hydrogen peroxide) solution. Finally, the oral cavity and lips were moistened with 2 grams of Toothette ® Oral Care Mouth Moisturiser, a water-based moisturiser containing vitamin E to promote the healing of lesions. For the control group, oral care was also carried out three times per day. Each patient in this group underwent assessment of oral cavity and sputum with the use of the same structured form. Oral treatment was then administered using the conventional protocol as follows: Thorough cleaning of the oral cavity with a sponge and atraumatic clamp was completed, followed by spreading throughout the oral cavity of Tarodent, which contains a 0.2% solution of chlorhexidine gluconate.
Antibiotic use
Antibiotics were used to treat both the study group and the control group. The antibiotics were divided into three groups. The first-line antibiotics included cephalosporins, quinolones, and macrolides. The second-line antibiotics included piperacillin-tazobactam. The third-line antibiotics included vancomycin, carbapenems, and anti-fungal and anti-viral drugs. Combinations of antibiotics were also used.
We use the first-line antibiotics for infections acquired outside of the hospital. The second line is used for hospitalacquired infections or for non-responders to first-line antibiotics. The third line is reserved for hospital-acquired infections or bacteria not sensitive to the first-or secondline antibiotics, or for outbreaks of viral infections, such as influenza.
Patient characteristics
Characteristics of the study population were summarized through descriptive statistics (Table 1 ). In the study group, 55.5% of the patients were male. The age range was 21 to 93 years; mean age was 68.7 years (SD, 15.6). In the control group, 53.3% of the patients were male. The age range was 27 to 88 years; mean age was 71.8 (SD, 14.8). Demographic characteristics did not differ significantly between the study and control groups (p> 0.34).
There were no statistically substantial differences in primary diagnosis between the two groups (p>0.65) ( Table 2) . The largest differences, however, occurred with regard to patients with cardiovascular disease (22.2% in the study group; 33.3% in the control group (p=0.239)), and patients who had undergone surgery/trauma (33.3% in the study group; 24.4% in the control group (p=0.352)). The mean APACHE II score was 19.1 (SD, 3.2) in the study group, and 18.2 (SD, 3.5) in the control group (p= 0.73) ( Table 2 ). Patient baseline characteristics were similar across groups, providing a good baseline for comparison.
The diagnosis of VAP was based upon NHSN criteria. An independent person reviewed the data and decided whether the diagnosis of VAP could be made. This person was unaware of the group allocation of the patient. Statistical analyses were performed by the hospital statistician.
Statistical analysis
The data were analyzed using SAS ® 9.2 software. Categorical variables were compared using the chi-square test and Fisher exact test. Comparisons of matched subjects with respect to the number of days of first-, second-, and third-line antibiotic use were performed using the Wilcoxon rank-sum test. A p value < 0.05 was considered statistically significant.
Results
During the study period, among the 90 patients admitted to the ICU, 8.9% of the study group developed VAP compared There were no statistically significant differences in demographic characteristics between the two groups (p >0.34).
with 33.3% of patients in the control group (p< 0.004). The development of VAP per 1,000 ventilation days was 10.2 in the study group, and 29.5 in the control group (p< 0.06) ( Table 3) . Hospital mortality did not differ significantly between the study and control groups (26.7% vs. 28.9%, respectively (p< 0.46). However, patients in the study group spent a mean of 11.09 days in the ICU; those in the control group spent 14.98 days (p< 0.151). The mean number of days on a ventilator was 8.39 in the study group vs. 12.69 in the control group (p< 0.044). The mean number of days of hospitalisation was 25.38 in the study group, and 31.71 in the control group (p< 0.02). The study group patients had a mean of 7.2 treatment days with antibiotics compared with 9.7 in the control group (p< 0.413). The study group had a mean of 5.76 treatment days with first-line antibiotics compared with 8.97 in the control group (p = 0.0267), 5.58 treatment days with second-line antibiotics compared with 7.42 in the control group (p = 0.1820), and 7.93 treatment days with third-line antibiotics compared with 9.92 in the control group (p = 0.2255).
Discussion
Dental plaque and other components of the oral cavity serve as perfect breeding grounds for pathogenic bacteria (Garcia et al, 2004; Fields, 2008) . In patients who are ventilated, a comprehensive oral hygiene treatment regimen that involves tooth brushing, suctioning, rinsing with an antiseptic, and moisturising is more effective in preventing VAP than more conventional protocols. Fields (2008) conducted a randomised, controlled trial in a 24-bed ICU with stroke patients randomised to usual VAP prevention measures plus timed tooth brushing vs. the usual VAP prevention measures. This study demonstrated that a regimen including comprehensive oral care decreased the occurrence of VAP. The VAP rate dropped to zero within one week of beginning the every-eight-hours suction toothbrushing regimen in the intervention group. The study was amended after six months, dropping the control group, because VAP rates decreased so dramatically. From then on, all intubated patients' teeth were brushed every eight hours, maintaining a zero rate until the study was completed (Fields, 2008) .
These and other studies have prompted various government and medical organisations to include comprehensive oral care as part of their guidelines for preventing VAP. The American Association of Critical-Care Nurses (AACN), the Institute for Healthcare Improvement (IHI), the Centers for Disease Control and Prevention (CDC), and the International Nosocomial Infection Control Consortium (INICC) refer to the importance of including daily and comprehensive oral care in controlling pneumonia (Tablan et al, 2004; Al-Tawfiq and Abed, 2010; Lynn-McHale Wiegand, 2011; Rosenthal et al, 2012) .
While the overall patient characteristics in our study did not differ significantly, the study group contained proportionately more surgery/trauma patients than the control group (33.3% vs. 24.4%, p = 0.352), as well as more infected patients (17.8% vs. 11.1%, p = 0.368) and fewer patients with cardiovascular disease (22.2% vs. 33.3%, p = 0.239). These patient characteristics demonstrate that the patients were well matched for their primary diagnosis, yet it appears that the study group contained proportionately more high-risk patients. Thus, our results are not confounded by underlying disease state.
The oral care regimen administered to our study group included use of an antiseptic containing 1.5% hydrogen peroxide compared with that of the control group, which contained 0.2% chlorhexidine gluconate. Our intent is not to press any antiseptic preference. We actually believe that chlorhexidine gluconate is a potent and very effective oral antiseptic and probably our top choice for a VAP prevention protocol as also was endorsed by the British Association of Critical Care Nurses (BACCN), though at lower concentrations such as 0.12% in order to avoid chlorhexidine gluconate potential side effects. Our approach indeed aims to highlight that a good antiseptic needs to be part of an integrated and comprehensive oral care protocol. Furthermore, the efficacy of any oral antiseptic could be compromised if dental plaque is not consistently removed, underscoring the importance of tooth brushing.
In The research performed in our facility sought to address the same types of VAP-related challenges facing British and European acute care facilities, and demonstrated in a statistically successful manner that these components are indeed important elements in any bundle targeting the control of pneumonia-associated pathogens. We know that hospital costs increase substantially with additional ventilation and hospitalisation days. Acquired pneumonia in ventilated patients contributes to the economic burden because of the need for more ventilation and hospitalisation days. We found a statistically significant reduction in the mean number of ventilation days and in the mean number of hospitalisation days between the study and control groups. Although our study did not show a difference in mortality rates between the study and control groups, a reduction in the factors contributing to economic burden is enough to justify promotion of an oral hygiene treatment regimen that is comprehensive and proven to reduce VAP rate in ICU patients.
Study limitations
We conducted a prospective, controlled study that was unblinded. Patients were alternately allocated to either the study or control group. The unblinded nature of the study has the potential to introduce bias. Patients received varying antibiotic regimens, which could have affected VAP rates. Finally, providers of oral care could have varying skill in the application of the protocol, introducing the possibility of operator bias.
Recommendations
We propose the following recommendations with regard to oral hygiene treatments in ventilated patients:
1. The continued tracking of the development of VAP in ICU patients 2. Ongoing awareness of VAP prevention through continued education of the team -emphasizing the importance of timely and proper mouth cleaning 3. Inclusion of suction tooth brushing two to three times a day as part of the oral hygiene protocol of the ICU 4. A continuation of the discussion of additional ways to reduce VAP in ventilated patients 5. A standardization of oral hygiene treatment protocols among ICU medical teams 6. Implementation of oral hygiene treatment protocols in other hospital facilities treating ventilated patients.
